- 1 Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and
- 2 could prevent future surges in some populations: a modeling study
- 3 Billy J. Gardner, B.A., A. Marm Kilpatrick, PhD*
- 5 Department of Ecology and Evolutionary Biology, University of California, Santa Cruz,
- 6 California, USA

4

8

7 *akilpatr@ucsc.edu

Summary

9

- 10 **Background** Vaccines have greatly reduced the impact of COVID-19, but vaccine protection
- against milder disease and infection have waned significantly, especially for the Delta variant
- 12 (B.1.617.2). A third booster dose of two-dose vaccines could restore protection but the benefit of
- boosting immunity in younger healthy individuals and the resultant effects on transmission have
- 14 not been quantified.
- 15 **Methods** We develop relationships between neutralizing antibody titers and vaccine protection
- against both infection and transmission. We combine these relationships with data on waning and
- boosting of neutralizing antibody titers to examine the impact of third doses of Pfizer-BioNtech
- and Moderna vaccines on infection and transmission and the impact on the pathogen effective
- 19 reproductive number R_t.
- 20 **Findings** Waning reduced protection of the Pfizer-BioNtech vaccine against all infections from
- 21 80.0% (95% CI: 77% to 83%) to 60.4% (95% CI: 53% to 67%), and for the Moderna vaccine
- 22 from 83.8 (95% CI: 80 to 87%) to 65.9% (95% CI: 61-71%). A third dose increased neutralizing
- antibody titers 25.9-fold relative to waned levels for the Pfizer-BioNtech vaccine and 13-fold
- relative to waned levels for the Moderna vaccine. This increased protection against infection to
- 25 87.2% (95% CI: 83% to 91%) and 86.3% (95% CI: 82% to 90%) for Pfizer and Moderna,
- 26 respectively. Increased protection against infection and transmission from third doses reduced R_t
- by 28% to 74% depending on vaccine coverage and previous infection and reduced R_t below 1
- 28 when vaccination coverage was high or contact rates were well below pre-pandemic levels.
- 29 **Interpretation** A third vaccine dose could substantially reduce transmission of SARS-CoV-2
- and prevent future surges, with the impact increasing with vaccine coverage and contact rates
- 31 among individuals. Reducing transmission would reduce infection in both unvaccinated
- individuals and breakthrough infections in vaccinated individuals.
- **Funding** California Department of Health, National Science Foundation
- 34 **Keywords** COVID-19; vaccination; waning immunity; herd immunity

Introduction

36

- 37 The emergence of the Delta variant (B.1.617.2) of SARS-CoV-2 has caused a surge of infections
- 38 globally, even in populations with high vaccination coverage (1, 2). This is due, in part, to the
- much higher infectiousness of this virus variant (2, 3), moderate immune evasion (4-6), and,
- 40 increasingly, waning vaccine immunity. Waning immunity is evident in both levels of
- 41 neutralizing antibodies (7-10) and studies of vaccine effectiveness (11-13). Several countries
- have recently offered third doses to individuals at higher risk of severe disease (14) because
- protection for these individuals, even against severe disease, has waned the most (11). However,
- 44 protection against severe disease for heathy individuals has waned far less and the need and
- benefit of providing third doses for young healthy individuals has been questioned (15). Many
- 46 populations, especially those in Africa, have received very few vaccine doses and many have
- argued that vaccinating these populations would provide a larger public health benefit than
- providing third doses to already vaccinated individuals (15) and for reducing the evolutionary
- 49 potential of the virus (16).
- 50 While the direct benefit of providing third doses to elderly and other at-risk individuals is now
- clear (17), the indirect benefit for reducing transmission of SARS-CoV-2 has not been
- 52 quantified. Most studies examining waning of vaccine effectiveness over time have focused on
- protection against symptomatic disease (11-13). The impact of waning immunity and boosting
- on vaccine protection against all infections (symptomatic and asymptomatic) and against virus
- transmission has been mentioned (15), but not quantified, despite its potential importance for
- reducing infection in unvaccinated individuals and breakthrough infections in vaccinated
- 57 individuals.
- 58 Here we extend a previous approach that showed strong correlations between a measure of
- 59 immunity, neutralizing antibody titers and vaccine protection (18). This study examined
- 60 protection against symptomatic disease against non-Delta variants using data from randomized
- control trials (18). We extend this approach by mapping neutralizing antibody titers to protection
- against both symptomatic disease and all infections, and against transmission, for both Delta and
- 63 non-Delta variants. We then use measurements of waning neutralizing antibody titers and
- boosting with a third dose to estimate the impact on protection against all infections, and the
- reproductive number of the virus, R_t which quantifies the average number of cases that each case
- 66 goes on to infect.

Methods

67

68

- 69 Protection against infection, disease, and transmission
- 71 We collected data from the literature (including ongoing systematic reviews: (19, 20)) on
- 72 protective efficacy and effectiveness of vaccines and convalescent sera for SARS-CoV-2 and
- 73 categorized each study by virus variant type (Delta and non-Delta; estimates of protection
- against the Beta variant were excluded) and study endpoint (symptomatic infections and all
- 75 infections) (Table S1). We excluded studies of protection where the endpoint was "any

infection" because these studies do not capture all infections and include an unknown fraction of asymptomatic infections. We also obtained an estimate of vaccine effectiveness against transmission (given infection) for Astrazeneca (ChAdOx1) and Pfizer-BioNTech (BNT162b2) vaccines for the Delta variant (21). This study quantified secondary attack rates using qPCR tests of contacts that were symptomatic or tested positive using lateral flow tests (21). It may have missed some asymptomatic or mildly symptomatic infected contacts, and thus provides only a crude estimate of protection. We gathered neutralizing antibody titer data for each vaccine and ratios of titers to convalescent sera from (18). Finally, we estimated the ratio of neutralizing antibody titers to the Delta variant relative to earlier variants (Table S2), and used these to adjust neutralizing antibody titer ratio estimates in analyses with vaccine effectiveness or protection from previous infection against the Delta variant (Table S1).

Estimating neutralizing antibody titers after waning and third doses

76

77

78 79

80

81

82

83

84

85 86

87

88 89

90

91 92

93

94 95

96

97

98

99

100

101

102

103

104

105

106

107108

109

110111112

113114

115

116117

118

119120

121

We obtained data on neutralizing antibody titers following vaccination for the Moderna vaccine (9), the Pfizer-BioNTech vaccine, and following infection with SARS-CoV-2 (7) (starting when titers peak at 25 days post symptom onset (22)) at several time points between 1 month after the second dose and 8 months post second dose, as well as 1 month after a third dose (10, 23, 24). One of the studies for the Pfizer vaccine (23) reported data for two age groups separately (18-55) and 65+), so we weighted these estimates by the fraction of individuals in the age groups 18-60 and 60+ in the United States (71.0% and 29.0%), which is similar to the age distribution in the European Union (25). We fit waning antibody titer data to a 3-parameter exponentially decaying function ($v = c_0e^{c_1*t} + c_2$) to estimate the neutralizing antibody titer on any day, t, post vaccination (Figure 2; Table S4). We fit several models with additional parameters reflecting differences in the waning rate (c1) or asymptote (c2 and c0) between antibodies derived from the two vaccines or natural immunity. We also estimated waning protection for hybrid immunity following infection and vaccination. Rates of waning for hybrid immunity with Pfizer-BioNtech and Moderna vaccines (combined) were statistically similar to rates of waning following vaccination with Pfizer-BioNtech (8), so we used the same relative rates of waning as for Pfizer-BioNtech (Figure 2; Table S4) but adjusted titers for the 7.9-fold higher initial level in those with hybrid immunity (8). We assumed that boosting individuals that had been infected and then vaccinated resulted in similar neutralizing antibody titers as people that had been vaccinated but not previously infected, because after 6 months of waning post-vaccination, these individuals with hybrid immunity had neutralizing antibody titers that had fallen below levels for newly vaccinated individuals (8).

Linking protection against infection and disease with neutralizing antibody titers

We modeled the relationship between protection from SARS-CoV-2 infections or disease and the ratio of neutralizing antibody titers relative to convalescent sera using a generalized linear model with a binomial distribution and a logit link, following a previous approach (18). In this analysis each data point is a single study of protection against SARS-CoV-2 infection or disease for a single virus variant. We included an interaction between neutralizing antibody titers and variant-endpoint to estimate separate relationships for each of four variant-endpoints (pairwise combinations of Delta and non-Delta, symptomatic disease, and all infections). We used the separate relationship for the Delta – all infections endpoint for all analyses described below.

The raw data for each estimate of protection (vaccine efficacy, vaccine effectiveness, or protection from previous infection) were unavailable, so we determined the effective sample sizes for a sample from a binomial distribution that matched the confidence intervals of the protection estimates (Table S1). We used the fitted model (Figure 1) to estimate protection against all infections for the Delta variant for both Moderna and Pfizer - BioNTech vaccines using neutralizing antibody titers measured after 6-8 months of waning and titers measured after a 3rd dose (23, 24). We performed a similar analysis using the limited data available to link neutralizing antibody titers to protection against transmission given infection (21) (Figure S1).

The impact of a third dose on the reproductive number, R_t

We used patterns of waning and boosting of neutralizing antibody titers and the relationships between neutralizing antibody titers and protection against all infections and transmission to estimate the impact of providing a third dose of Moderna and Pfizer – BioNTech vaccines to increasing fractions of vaccinated individuals on the reproductive number of SARS-CoV-2, Rt. The effective reproductive number, R_t , is the average number of secondary cases that each case infects. It is equal to the basic reproductive number for a fully susceptible population, R₀, multiplied by the fraction of the population that is still susceptible. We split the population based on vaccination and infection to determine the effective fraction susceptible: fraction previously infected and unvaccinated, fpu, fraction previously infected and vaccinated, fpv; fraction unvaccinated, fu, fraction vaccinated (with two doses of either Pfizer-BioNtech or Moderna), fv, and fraction boosted with a third dose, f_B (f_U+f_V+f_B=1). We estimated the susceptibility of each group using estimates of the protection against infection, VE_I, (Figure 1) and the reduced probability of transmitting given infection, VE_T, (Figure S1) for each group using the subscripts above, except VE_{IH} and VE_{TH} which are estimates of protection from hybrid immunity from infection and vaccination. We used these estimates of protection to calculate R_t for five groups of people: fully susceptible unvaccinated (1-f_P)f_U, previously infected unvaccinated f_Pf_U, previously uninfected vaccinated (1-f_P)f_V, previously infected vaccinated f_Pf_V, and previously uninfected vaccinated and boosted with a third dose (1-f_P)f_B:

```
R_{t} = R_{0} \left[ (1-f_{PU})f_{U} + f_{PU}f_{U}(1-VE_{IP})(1-VE_{TP}) + (1-f_{PV})f_{V}(1-VE_{IV})(1-VE_{TV}) + (f_{PV}f_{V})(1-VE_{IH})(1-VE_{TH}) + (f_{B})(1-VE_{IB})(1-VE_{TB}) \right]
```

We examined the effect of boosting vaccinated individuals with a third dose by considering five scenarios that differ in contact rates/ R_0 ($R_0 = 3.7$ or 7 reflecting mid-summer 2021 levels in the USA and pre-pandemic behavior, respectively), vaccination coverage (59%, 69%, 75% and 100%), and the fraction of the population previously infected (1.0%, 28.5% and 56.9%), with the last value being similar to estimates of the fraction of the USA population that had been infected by late-November, based on 44 million cases and an infection to case ratio of 4.2 (26)). The scenarios and rationale were (Table S5):

1) R0 = 3.7, 59% vaccinated, 56.9% previously infected: approximates USA population in late-November with contact rates similar to summer 2021, as might occur in winter 2021

- 2) R0 = 3.7, 69% vaccinated, 1.0% previously infected: approximates countries/populations that effectively suppressed transmission and haven't yet reached high vaccination levels and have somewhat reduced contact rates (e.g. New Zealand, Australia, Hong Kong, etc.)
- 3) R0 = 3.7,75% vaccinated, 28.5% previously infected: approximates some populations with higher vaccination and lower fraction infected than scenario (1) (e.g. California)
- 4) R0 = 7, 100% vaccinated, 56.9% previously infected: a hypothetical optimistic scenario to compare to scenario (1) to determine if vaccination with or without boosting could limit transmission if behavior returns to pre-pandemic levels
- 5) R0 = 7, 59% vaccinated, 56.9% previously infected: a more realistic scenario to compare to scenario (1) to determine if boosting could limit transmission if behavior returns to pre-pandemic levels

For all scenarios we estimated the waning of vaccine-derived immunity as of late November, 2021 using the timing of vaccination in the USA (27) (Figure S2) and patterns of waning neutralizing antibody titers over time for Pfizer-BioNtech and Moderna vaccines or hybrid immunity (Figure 2). We estimated the waning of infection-derived immunity as of late November, 2021 using the timing of deaths in the USA (25) shifted by 24 days (28) (Figure S3) and the rate of waning of infection-derived immunity (Figure 2). We estimated the number of infections in vaccinated and unvaccinated people using the ratios of cases in these two groups over time in the USA (29) (Figure S4). We used these data on the timing of vaccination and infection and rates of antibody waning to determine the protection against infection and transmission as of late November, 2021 (Table S6). We calculated 95% CIs for predicted values of R₁ that incorporated uncertainty in the relationships between neutralizing antibody titers and protection against infection and transmission (Figures 1 and S4). We drew 10,000 samples from a uniform distribution between 0 and 1 and used these as quantiles for a normal distribution to generate draws (on a logit scale) for values of protection VE for each value of neutralizing antibody titer adjusted for waning for the fraction of the population that was vaccinated or infected at each day in the past. This approach essentially drew a single line from the 95% CI of lines in Figure 1 and used that for all levels of waning. We then inverse-logit transformed these values of VE and used them to generate 10,000 values of R_t for that scenario. We took the 2.5% and 97.5% quantiles to estimate the 95% confidence intervals (CIs) for R_t for each point of each scenario.

Results

166

167

168

169

170

171

172

173

174

175176

177

178

179

180

181 182

183

184 185

186

187

188

189

190

191

192

193

194 195

196 197

198

199

200

201

202

203

204

205

There were very strong relationships between protection against both symptomatic infection and all infections and the ratio of vaccine neutralizing antibody titers relative to convalescent sera (Figure 1; Table S3). Protection was highest for symptomatic disease for non-Delta variants and lower for protection against all infections for both non-Delta and Delta variants (Figure 1; Table S3).




Fig. 1. Protection against symptomatic infections or all infections plotted against the ratio of neutralizing antibody titers relative to convalescent sera. Each round point represents an estimate of vaccine efficacy for a single vaccine & virus variant (from randomized control trials) or vaccine effectiveness (from observational studies) or an estimate of protection from previous infection from observational studies. Square points show predicted values using the fitted model and measured neutralizing antibody titers after waning (Moderna: 6 months; Pfizer 8 months) or boosting. Colors show the SARS-CoV-2 variant (Delta or non-Delta) and endpoint of the study (symptomatic infections or all infections). Closed symbols and 95% CIs show aggregated data for each vaccine-variant-endpoint. Open symbols show estimates from individual studies if there were more than one estimate for a vaccinevariant-endpoint. Points have been jittered along the x-axis to facilitate presentation; all points for the same vaccine-variant have the same x-value. Lines show fitted models with protection as the response and an interaction between and neutralizing antibody ratio and variant-endpoint as predictors (Table S3). Panel B shows data and relationships for the Delta variant, with all points shifted 2.88-fold lower along the x-axis to reflect the lower neutralizing antibodies observed with this variant across studies (Table S2).

206

207

208209

210

211212

213

214215

216217

218

219220

221

Neutralizing antibody titers waned approximately 8-fold for vaccine-derived immunity (for both Pfizer-BioNtech and Moderna vaccines) and 3-fold for infection derived immunity, with fastest waning in the first 3-5 months (Figure 2A, B). Rates of waning were fastest for the Pfizer-BioNtech vaccine, followed by infection-generated antibodies, and antibodies from the Moderna vaccine waned the slowest (Figure 2B; Table S4). Antibodies from infection stabilized at a slightly higher level relative to their peak than either vaccine (Figure 2B), but starting neutralizing antibody titers were lowest for infection, followed by Pfizer-BioNtech and then Moderna (Figure 2A).




Figure 2. Waning of neutralizing antibodies and protection against infection over time and boosting with third doses. A) Neutralizing antibody titers relative to convalescent sera, adjusted for lower neutralization titers with the Delta variant. B) The same data as in panel A but rescaled relative to the peak initial value (i.e. all lines start at a value of 1) so rates of waning and relative levels of stabilization can be visualized and analyzed simultaneously (Table S4). C) Protection against infection over time using the patterns of waning in Panel A and the relationships between antibody titers and protection against infection (Figure 1B, red line). Points in the upper hand corner show the effect of third doses in boosting protection for the Pfizer and Moderna vaccines.

- We used the strong relationship between neutralizing antibody titers and protection against
- infection for the Delta variant (Figure 1; Table S3), and patterns of waning of antibody titers
- 243 (Figure 2A, B) to estimate the waning of protection against all infections over time (Figure 2C).
- 244 Protection against all infections was highest for Hybrid immunity (infection followed by
- vaccination), followed by Moderna, Pfizer-BioNtech vaccines, and then infection-derived
- immunity. The relatively fast and sustained waning rate of neutralizing antibodies for the Pfizer-
- 247 BioNtech vaccine suggests that protection from this vaccine was initially much higher than
- 248 infection-derived immunity but the two were similar after four months (Figure 2C). Specifically,
- waning of neutralizing antibody titers reduced protection against all infections for the Delta
- variant for the Pfizer-BioNtech vaccine from 80.0% (95% CI: 77.0% to 83.0%) to 60.4% (95%
- 251 CI: 53.3% to 67.2%) (Figure 2, purple line and Figure 1, red line, compare points labelled
- 252 "Pfizer orig" to "Pfizer waned"). Waning of neutralizing antibodies also reduced the protection
- against transmission given infection for the Pfizer-BioNtech vaccine from 38% (95% CI: 28% to
- 254 47%) to 10.5% (95% CI: 6.6% to 16.4%) (Figure S1).
- A third dose of the Pfizer-BioNtech vaccine boosted antibody titers 26-fold relative to levels
- after 8 months of waning, or 25.9/8.1 = 3.2-fold higher than one week after dose 2 (23). A third
- dose of the Moderna vaccine boosted antibody titers 13-fold relative to waned levels, or 1.5-fold
- 258 higher than after the 2nd dose. The fitted relationship between protection and antibody titers
- 259 (Figure 1; Table S3) suggests third doses of the Pfizer-BioNtech vaccine would increase
- protection against infection from an eight-month waned value of 60.4% (95% CI: 53.3% to
- 261 67.2%) to a boosted value of 87.2% (95% CI: 82.8% to 90.7%) (Figure 2C) and would boost
- protection against transmission given infection from 10.5% to 60.7% (95% CI: 42.3% to 76.5%)
- 263 (Figure S1). For the Moderna vaccine, a third dose would increase protection against infection
- 264 from a waned value of 65.8% (60.9-70.5%) to a boosted value of 86.3% (82.0-89.7%), and
- 265 would increase protection against transmission (given infection) from a waned value of 14.9%
- 266 (10.8-20.2%) to a boosted value of 57.2% (40.3-72.6%) (Figure S1).
- Next, we examined the impacts of third doses on population level transmission. Boosting
- 268 immunity, by providing a third dose of the Pfizer-BioNtech vaccine to all doubly vaccinated
- 269 individuals in the USA (59% of the total population), could reduce the reproductive number R_t
- by 28% from 1.26 to 0.91 and stop a surge (Figure 3, red line), assuming current levels of
- vaccination coverage (59%), estimated immunity from previous infection (56.9%), and behavior
- 272 consistent with the summer Delta surge (R₀=3.7) (see Methods for further details).
- 273 Unfortunately, in places where vaccination is slightly higher (69%), but previous infection is
- much lower, (1.0%; e.g. New Zealand), boosting with a third dose would be unable to prevent a
- surge with the same contact rates (Figure 3, grey line). Conversely, in populations where
- vaccination is higher (75%) and previously infection is lower (28.5%) (e.g. California), boosting
- at least 50% of the population (67% of those vaccinated) could push R_t below 1 (Figure 3 blue
- 278 line).
- 279 If contact rates return to pre-pandemic levels (R₀=7), with late November USA vaccine coverage
- 280 (59%) and infection history (56.9%), then boosting could reduce R_t by a larger absolute amount
- (but the same relative amount, 28%) than with lower contact rates, from 2.38 to 1.72 (Figure 3,

282

283 284

285

286 287

288

289

290

291

292

293294

295

296

297

298

299

300

301

302

303

304

305

306

307

green line) but cases would still rise rapidly because 1.72 is still far above 1. Using the same number of 3rd doses to doubly vaccinate unvaccinated individuals would be more impactful, and could reduce R_t to 1.49 (Figure 3, compare right end of green line to black point labelled 88.5% vaccinated on left side). If contact rates return to pre-pandemic levels (R₀=7), then even if a population had 100% vaccination coverage and 56.9% previously infected, waning of vaccine and infection-derived immunity would cause cases to continue to grow without boosting (Figure 3, left end of yellow line: R_t=1.33 which is greater than 1; without waning R_t would be 0.80, well below 1). However, boosting at least 34% of a fully (100%) vaccinated population would reduce R_t below 1 and thus could prevent a surge in cases, even with pre-pandemic behavior (Figure 3, yellow line); boosting the entire population with a third dose would reduce Rt by 74% (from 1.33 to 0.35). Note that three scenarios (Fig 3, red, blue, and yellow lines, representing moderate vaccination and infection, high vaccination and low infection, and complete vaccination and moderate infection but pre-pandemic behavior, respectively) all produce similar values of R_t, because vaccination and infection contribute similarly to immunity after waning (Figure 2C), and very high immunity (through vaccination or infection) is needed to balance pre-pandemic behavior.




Figure 3. Relationship between third dose coverage and the pathogen effective reproductive number, R_t . Lines and 95% CIs show the estimated reproductive number for five scenarios (see Methods). The single black point shows the impact of using all third doses from the right end of the green line to doubly-vaccinate unvaccinated individuals, which would bring the vaccination coverage from 59% to 88.5%. Protection from vaccination and previous infection for all lines reflect waning, as described in the Methods (Table S3). The dashed horizontal line shows the threshold reproductive number $R_t = 1$, separating a growing from a shrinking epidemic.

Discussion

308

326

337

348

Vaccines have greatly reduced the impact of COVID-19 globally, but waning immunity and the

emergence of the Delta variant have led to surges in cases despite high vaccination coverage in

many populations (1, 7-10). This has led to many countries recommending third doses to boost

immunity to protect at-risk individuals (14). However, the impact of third doses on transmission

of SARS-CoV-2 has received far less attention (15), and no study has empirically estimated the

314 impact of third doses on infection, transmission, and the reproductive number R_t.

We found that a third dose could substantially reduce transmission, especially in highly

vaccinated populations, and the absolute effect was larger when contact rates (which scale R₀)

were higher. We showed that neutralizing antibodies are strongly correlated not just with

protection against symptomatic disease (4, 18), but also with protection against all infection and

transmission given infection (Figures 1, S4). These relationships allowed us to estimate the effect

of waning and boosting on transmission, and the pathogen reproductive number R_t. Boosting

immunity by providing a third dose to individuals vaccinated more than three months ago (after

most waning has occurred: Figure 2) could reduce transmission substantially and could prevent a

winter surge in many populations where vaccination coverage is high, as long as contact rates

and behavior don't fully return to pre-pandemic levels. In contrast, with pre-pandemic contact

rates, only very high levels of vaccine coverage, and a combination of a moderate level of

previous infection and boosting could prevent a surge.

We also found that despite the substantial potential impact of boosting on transmission,

deploying vaccine doses to unvaccinated individuals has a larger effect on transmission (Figure

329 3, compare the black point to the right end of the green line). In addition, the direct effect of

vaccinating unvaccinated people is much larger than the benefit of providing a third dose for

severe disease and death since protection against severe disease has only waned slightly, except

in older or at-risk individuals (11). Unfortunately, vaccine hesitancy among those not vaccinated

is quite high in many populations (e.g., USA, Russia, etc.) and many people are unwilling to get

vaccinated despite strong incentives, often due to misinformation (30-32), making it difficult to

increase vaccine coverage in some populations. In contrast, there other populations where

vaccine coverage is very low, primarily due to poor availability, especially in parts of Africa

(33). Clearly, limited vaccine doses would be most effectively used in these populations and

should be deployed there until supplies are no longer limiting.

Our study has several limitations. First and foremost is the reliance on neutralizing antibody

340 titers as a predictor of protection against infection and transmission. Although the analyses here,

and elsewhere suggest a strong relationship between neutralizing antibody titers and protection at

the population level (4, 18) and individual level (34), other parts of the immune system, such as

T-cells, also play key roles in protection, especially against severe disease. Second, our analyses

344 use population averages for estimates of protection against infection and transmission and ignore

age-specific variation among individuals (as well as other factors). Third, the data available to

estimate vaccine protection against all infections and against transmission given infection from

the Delta variant was limited. Fourth, it's unclear how long antibody titers will be elevated

following a third dose, so the effect of boosting might not last long. Finally, we assume well-

- mixed populations in calculating reductions in the reproductive number R_t. Clearly a targeted
- vaccination approach would be more effective than that outlined here if individuals that were
- 351 highly connected could be targeted for third doses (35).
- In summary, many countries have already begun to deploy third doses to protect at-risk
- individuals, and some countries (e.g. Israel, the UK, and the USA (17)) have started to deploy
- third doses to the general population. However, uptake in most countries has been low, criteria
- for third doses have been vague and confusing (14), and only moderate effort has been expended
- to deploy third doses widely. Our results suggest that widespread boosting of the general
- population could substantially reduce transmission. Polls in some countries suggest a large
- fraction of the vaccinated population would be willing to get a third dose (e.g., 76% of
- Americans; (36)). If vaccine doses for providing initial doses to populations with very low
- 360 coverage are not limiting, then offering third doses to the general public could play a significant
- role in reducing transmission. This would directly protect boosted individuals (37), indirectly
- protect unvaccinated and vaccinated individuals, and reduce the possibilities for viral evolution
- 363 (16).

364

365 Contributors

AMK conceived the study. BJG and AMK performed the analyses and wrote the paper.

367 **Declaration of interests**

368 All authors declare no competing interests.

369 **Data sharing**

- Code and data files to replicate the figures and analyses of this paper can be found at:
- 371 https://github.com/marmkilpatrick/Vaccine-boosters

372 Acknowledgements

We thank the Kilpatrick lab for helpful comments.

374 References

- Wadman M. Israel's grim warning: Delta can overwhelm shots. Science.
- 376 2021;373(6557):838-9.
- 2. Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, et al. Exponential growth,
- 378 high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
- 379 Science.0(0):eabl9551.
- 380 3. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al.
- Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.
- 382 Eurosurv. 2021;26(24):2100509.
- van Gils MJ, Lavell AHA, van der Straten K, Appelman B, Bontjer I, Poniman M, et al.
- Four SARS-CoV-2 vaccines induce quantitatively different antibody responses against SARS-
- 385 CoV-2 variants. medRxiv. 2021:2021.09.27.21264163.

- Davis C, Logan N, Tyson G, Orton R, Harvey W, Haughney J, et al. Reduced
- neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
- 388 medRxiv. 2021:2021.06.23.21259327.
- 389 6. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature.
- 391 2021;596(7871):276-80.
- Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, et al.
- Neutralization of VOCs including Delta one year post COVID-19 or vaccine. medRxiv.
- 394 2021:2021.08.12.21261951.
- 395 8. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al.
- mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.
- 397 Science. 2021:eabm0829.
- 9. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, et al.
- 399 Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-
- 400 19. N Engl J Med. 2021;384(23):2259-61.
- 401 10. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune
- 402 humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021.
- 403 11. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Vaccine
- 404 effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and
- severe COVID-19 in the UK. medRxiv. 2021.
- 406 12. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Haas E, et al.
- Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. medRxiv. 2021.
- 408 13. Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yassine HM, Benslimane FM, et al.
- Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J
- 410 Med. 2021.
- 411 14. Furlong A, Deutsch J. A country-by-country guide to coronavirus vaccine booster plans
- 412 2021 [Available from: https://www.politico.eu/article/vaccine-booster-coronavirus-covid-19-
- 413 europe-delta-varian-who/.
- 414 15. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al.
- 415 Considerations in boosting COVID-19 vaccine immune responses. Lancet (London, England).
- 416 2021;398(10308):1377-80.
- 417 16. Wagner CE, Saad-Roy CM, Morris SE, Baker RE, Mina MJ, Farrar J, et al. Vaccine
- 418 nationalism and the dynamics and control of SARS-CoV-2. medRxiv. 2021.
- 419 17. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.
- 420 Protection of BNT162b2 vaccine booster against covid-19 in Israel. N Engl J Med.
- 421 2021;385(15):1393-400.
- 422 18. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic
- 424 SARS-CoV-2 infection. Nat Med. 2021:1-7.
- 425 19. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic
- review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and
- 427 disease. medRxiv. 2021:2021.09.17.21263549.
- 428 20. WHO. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic
- Review 2021 [Available from: https://view-hub.org/sites/default/files/2021-
- 430 09/COVID19%20VE%20Studies_Forest%20Plots_1.pdf.

- 431 21. Eyre DW, Taylor D, Purver M, Chapman D, Fowler T, Pouwels KB, et al. The impact of
- 432 SARS-CoV-2 vaccination on Alpha and Delta variant transmission. medRxiv.
- 433 2021:2021.09.28.21264260.
- 434 22. Arkhipova-Jenkins I, Helfand M, Armstrong C, Gean E, Anderson J, Paynter RA, et al.
- 435 Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living
- 436 review. Ann Intern Med. 2021;174(6):811-21.
- 437 23. Falsey AR, Frenck Jr RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-
- 438 CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. N Engl J Med. 2021.
- 24. Chu L, Montefiori D, Huang W, Nestorova B, Chang Y, Carfi A, et al. Immune Memory
- 440 Response After a Booster Injection of mRNA-1273 for Severe Acute Respiratory Syndrome
- 441 Coronavirus-2 (SARS-CoV-2). medRxiv. 2021:2021.09.29.21264089.
- 442 25. CDC. COVID Data Tracker 2021 [Available from: https://covid.cdc.gov/covid-data-
- 443 <u>tracker/#vaccinations_vacc-total-admin-rate-total.</u>
- 444 26. CDC. Estimated COVID-19 Burden 2021 [Available from:
- https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html.
- 446 27. CDC. COVID-19 Vaccinations in the United States 2021 [Available from:
- 447 https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-total-admin-rate-total.
- Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al. Incidence,
- clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California
- and Washington: prospective cohort study. BMJ-British Medical Journal. 2020;369:10.
- 451 29. CDC. Rates of COVID-19 Cases and Deaths by Vaccination Status 2021 [Available
- from: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status.
- 453 30. Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine
- hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775-9.
- 455 31. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of
- vaccine acceptance rates. Vaccines. 2021;9(2):160.
- 457 32. Machingaidze S, Wiysonge CS. Understanding COVID-19 vaccine hesitancy. Nat Med.
- 458 2021;27(8):1338-9.
- 459 33. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of
- 460 COVID-19 vaccine in low-income countries. npj Vaccines. 2021;6(1):1-3.
- 461 34. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser D, Deng W, et al. Immune
- 462 Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. medRxiv.
- 463 2021:2021.08.09.21261290.
- 464 35. Firth JA, Hellewell J, Klepac P, Kissler S, Kucharski AJ, Spurgin LG. Using a real-world
- network to model localized COVID-19 control strategies. Nat Med. 2020;26(10):1616-22.
- 466 36. Aboulenein A, Kahn C. Most vaccinated Americans want COVID-19 booster shots -
- Reuters/Ipsos poll: Reuters; 2021 [Available from: https://www.reuters.com/business/healthcare-
- 468 pharmaceuticals/most-vaccinated-americans-want-covid-19-booster-shots-reutersipsos-poll-
- 469 2021-09-01/.
- 470 37. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of
- a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in
- 472 Israel: an observational study. The Lancet. 2021.
- 473 38. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness
- of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection
- and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ.
- 476 2021;374:n1943.

- 477 39. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA
- Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-
- 479 23.
- 480 40. Emary KR, Golubchik T, Aley PK, Ariani CV, Angus B, Bibi S, et al. Efficacy of
- 481 ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.
- 482 1.1. 7): an exploratory analysis of a randomised controlled trial. The Lancet.
- 483 2021;397(10282):1351-62.
- 484 41. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine
- coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine
- against infection (SIREN): a prospective, multicentre, cohort study. The Lancet.
- 487 2021;397(10286):1725-35.
- 488 42. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
- 489 Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med.
- 490 2021:585-94.
- 491 43. Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et
- al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and
- 493 hospitalisation, Navarre, Spain, January to April 2021. Eurosurv. 2021;26(21):2100438.
- 494 44. Narrainen F, Shakeshaft M, Asad H, Holborow A, Blyth I, Healy B. The protective effect
- of previous COVID-19 infection in a high-prevalence hospital setting. Clinical Medicine.
- 496 2021;21(5):e470.
- 497 45. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of
- 498 COVID-19 vaccines against variants of concern, Canada. Medrxiv. 2021.
- 499 46. Pouwels KB, Pritchard E, Matthews P, Stoesser NB, Eyre DW, Vihta K-D, et al. Impact
- of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the
- 501 UK. medRxiv. 2021.
- 502 47. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta K-D, et al. Impact of
- vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med. 2021:1-9.
- 504 48. Satwik R, Satwik A, Katoch S, Saluja S. ChAdOx1 nCoV-19 effectiveness during an
- 505 unprecedented surge in SARS COV-2 infections. European Journal of Internal Medicine. 2021.
- 506 49. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane F, Al Khatib HA, et al.
- 507 BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B. 1.617. 2)
- variant in Oatar. MedRxiv. 2021.
- 509 50. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-
- dose administration and the influence of the timing of the booster dose on immunogenicity and
- efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
- 512 The Lancet. 2021;397(10277):881-91.
- 513 51. Whitaker H, Tsang R, Byford R, Andrews N, Sherlock J, Pillai P. Pfizer-BioNTech and
- Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals
- in clinical risk groups. Khub net Posted July. 2021.
- 516 52. Richardson JR, Goetz R, Mayr V, Lohse MJ, Holthoff H-P, Ungerer M. SARS-COV2
- 517 mutant-specific T cells and neutralizing antibodies after vaccination and up to 1 year after
- infection. medRxiv. 2021.
- 519 53. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody
- activity against SARS-CoV-2 VOCs B. 1.617. 2 and B. 1.351 by BNT162b2 vaccination. The
- 521 Lancet. 2021;397(10292):2331-3.

522 54. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Ability of AZD1222
523 vaccination to elicit neutralising antibodies against SARS-CoV-2 VOC B. 1.617. 2 (Delta).
524 Lancet (London, England). 2021;398(10296):207.
525
526
527

Supplemental Tables and Figures

Table S1. Data and studies used to estimate the relationship between protection (VE) against infection, disease and transmission endpoints and neutralizing antibody titer (NAT) ratios relative to convalescent sera (Figure 1). A single value of the neutralizing antibody titer ratio was used for each vaccine and variant; values for the Delta variant are 2.88-fold lower than for non-Delta variants (Table S2). N_{eff} are the effective sample sizes used for the logistic regression (Table S3).

Study	Vaccine or	Variant	Endpoint	NAT Ratio	VE (95% CI)	Neff
	Convalescent					
(13)	Moderna	non-Delta	Symptomatic	4.13	0.99 (0.92-1.00)	70
(38)	Moderna	non-Delta	Symptomatic	4.13	0.94 (0.86-0.97)	112
(38)	Pfizer	non-Delta	Symptomatic	2.37	0.91 (0.88-0.93)	550
(39)	Pfizer	non-Delta	Symptomatic	2.37	0.94 (0.87-0.98)	96
(40)	Astrazeneca	non-Delta	Symptomatic	0.54	0.75 (0.42-0.89)	16
(21)	Astrazeneca	Delta	Transmission	0.19	0.16 (0.12-0.21)	243
(21)	Pfizer	Delta	Transmission	0.82	0.38 (0.28-0.47)	109
(41)	Convalescent	non-Delta	All infections	1	0.83 (0.76-0.87)	168
(41)	Pfizer	non-Delta	All infections	2.37	0.86 (0.76-0.97)	49
(18)	Astrazeneca	non-Delta	Symptomatic	0.54	0.62 (0.41-0.76)	34
(18)	Convalescent	non-Delta	Symptomatic	1	0.89 (0.66-0.98)	18
(18)	CoronaVac	non-Delta	Symptomatic	0.17	0.50 (0.36-0.62)	60
(18)	JJ	non-Delta	Symptomatic	0.47	0.67 (0.59-0.74)	147
(18)	Moderna	non-Delta	Symptomatic	4.13	0.94 (0.89-0.97)	150
(18)	Novavac	non-Delta	Symptomatic	3.97	0.96 (0.68-0.99)	25
(18)	Pfizer	non-Delta	Symptomatic	2.37	0.95 (0.90-0.98)	200
(18)	Sputnik	non-Delta	Symptomatic	1.41	0.92 (0.85-0.95)	140
(42)	Astrazeneca	Delta	Symptomatic	0.19	0.67 (0.61-0.72)	330
(42)	Astrazeneca	non-Delta	Symptomatic	0.54	0.75 (0.68-0.79)	240
(42)	Pfizer	Delta	Symptomatic	0.82	0.88 (0.85-0.90)	750
(42)	Pfizer	non-Delta	Symptomatic	2.37	0.94 (0.92-0.95)	720
(43)	Pfizer	non-Delta	Symptomatic	2.37	0.82 (0.73-0.88)	110
(44)	Convalescent	non-Delta	All infections	1	0.97 (0.81-1.00)	25
(45)	Astrazeneca	non-Delta	Symptomatic	0.54	0.91 (0.62-0.98)	22
(45)	Astrazeneca	Delta	Symptomatic	0.19	0.87 (0.69-0.95)	32
(45)	Moderna	non-Delta	Symptomatic	4.13	0.92 (0.88-0.95)	225
(45)	Moderna	non-Delta	Symptomatic	4.13	0.96 (0.85-0.99)	50
(45)	Moderna	Delta	Symptomatic	1.44	0.95 (0.91-0.97)	220
(45)	Pfizer	non-Delta	Symptomatic	2.37	0.89 (0.86-0.91)	1440
(45)	Pfizer	Delta	Symptomatic	0.82	0.92 (0.90-0.94)	600
(45)	Pfizer	non-Delta	Symptomatic	2.37	0.93 (0.88-0.95)	210
(46)	Astrazeneca	Delta	All infections	0.19	0.67 (0.62-0.71)	420
(46)	Astrazeneca	non-Delta	All infections	0.54	0.79 (0.56-0.90)	25

(46)	Convalescent	Delta	All infections	0.35	0.72 (0.58-0.82)	53
(46)	Convalescent	non-Delta	All infections	1	0.60 (0.50-0.68)	125
(46)	Pfizer	Delta	All infections	0.82	0.80 (0.77-0.83)	780
(46)	Pfizer	non-Delta	All infections	2.37	0.78 (0.68-0.84)	100
(47)	Astrazeneca	non-Delta	All infections	0.54	0.79 (0.65-0.88)	50
(47)	Pfizer	non-Delta	All infections	2.37	0.80 (0.73-0.85)	185
(48)	Convalescent	Delta	Symptomatic	0.35	0.93 (0.87-0.96)	169
(49)	Moderna	Delta	Symptomatic	1.44	0.86 (0.71-0.94)	42
(49)	Pfizer	Delta	Symptomatic	0.82	0.56 (0.41-0.67)	64
(50)	Astrazeneca	non-Delta	All infections	0.54	0.56 (0.41-0.67)	63
(51)	Astrazeneca	non-Delta	Symptomatic	0.54	0.78 (0.70-0.84)	150
(51)	Pfizer	non-Delta	Symptomatic	2.37	0.93 (0.86-0.97)	100

Table S2. Ratios of neutralizing antibody titers to Delta or non-Delta variants of SARS-CoV-2 from vaccination or infection SARS-CoV-2.

Reference	non-Delta variant	Sample type	Ratio non-Delta to Delta
(4)	D614G	Pfizer-BioNtech	4.5
(4)	D614G	Astrazeneca	4.5
(23)	Wild Type	Pfizer-BioNtech	1.28
(5)	Wuhan	Pfizer-BioNtech	11.30
(5)	Wuhan	Astrazeneca	4.01
(52)	Wild Type	Pfizer-BioNtech	2.1
(52)	Wild Type	Astrazeneca	2.1
(53)	Wild Type	Pfizer-BioNtech	5.8
(54)	Wild Type	Astrazeneca	8.0
(7)	Wild Type	Pfizer-BioNtech	1.18
(7)	Wild Type	Astrazeneca	1.22
(6)	D614G	Pfizer-BioNtech	2.0
(6)	D614G	Astrazeneca	5.0
(4)	D614G	Convalescent	2.1
(6)	D614G	Convalescent	2.1
		Estimated ratio*	2.88

*There was no significant difference in the ratios among sample types (either vaccines or convalescent sera): mixed effects model of log-transformed ratio with Sample Type as a fixed effect and study as a random effect; likelihood ratio $\chi^2(df=2) = 2.6$; P = 0.26.

Table S3. Logistic regression analysis of protection (vaccine efficacy or effectiveness or protection from previous infection) with the log-transformed ratio of neutralizing antibody titers (NAT-Ratio) relative to convalescent sera, with an interaction with four groups for variant (Delta and non-Delta) and endpoint (symptomatic cases or all infections) as shown in Figure 1. Delta – infection was the reference level.

Predictor	Estimate	SE	Z-value	P-value
Intercept	1.47	0.10	14.49	< 0.0001
log ₂ (NAT-Ratio)	0.32	0.064	4.97	< 0.0001
non-Delta – symptomatic	0.10	0.11	0.87	0.39
non-Delta – infection	-0.41	0.13	-3.00	0.0027
Delta – symptomatic	0.77	0.13	5.79	< 0.0001
log ₂ (NAT-Ratio):non-Delta - symptomatic	0.27	0.076	3.59	0.00034
log ₂ (NAT-Ratio):non-Delta - infection	-0.035	0.12	-0.29	0.77
log2(NAT-Ratio):Delta - symptomatic	0.22	0.089	2.50	0.012

Table S4. Analysis of waning rates of neutralizing antibodies for two vaccines (Pfizer-BioNtech and Moderna) and infection-derived immunity. The best fitting model by AIC was Antibody titer = $(c_0+c_7*Infection)*e^{(c_1*Day+c_3*Day*Moderna+c_4*Infection*Day)}+c_2+c_6*Infection$, where Pfizer-BioNtech was the reference level. There was no support for Moderna having a different asymptote than Pfizer (P-values>0.45 for coefficients similar to c_7 and c_6).

Coefficient	Estimate	SE	t-value	P-value
C 0	0.91	0.037	24.61	< 0.0001
C1	-0.022	0.0027	-8.25	< 0.0001
C 2	0.10	0.032	3.22	0.0074
C 3	0.011	0.0023	4.653	0.0006
C4	0.0083	0.0052	1.58	0.14
C ₆	0.20	0.054	3.64	0.0034
C 7	-0.21	0.074	-2.81	0.0157

Table S5. Fraction of the population in each group for the five scenarios in Figure 3, using the case ratios in vaccinated and unvaccinated individuals and the timing of vaccinations and infections derived from COVID-19 deaths and vaccinations as of late November, 2021 in the USA (Figures S2-S4).

Scenario	Fraction vaccinated and infected	Fraction vaccinated and not infected	Fraction unvaccinated and infected	Fraction fully susceptible ((1-f _{PU})*f _U)
	$(f_{PV}*f_V)$	$((1-f_{PV})*f_V)$	$(\mathbf{f}_{\mathrm{PU}}^{*}\mathbf{f}_{\mathrm{U}})$	((2 170) 10)
R0=3.7; 59%	0.27	0.32	0.29	0.12
vacc., 56.9%				
prev. inf.				
R0=3.7; 69%	0.0035	0.69	0.0065	0.30
vacc., 1.0%				
prev. inf.				
R0=3.7; 75%	0.18	0.57	0.11	0.14
vacc., 28.5%				
prev. inf				
R0=7; 100%	0.569	0.431	0	0
vacc., 56.9%				
prev. inf.				
R0=7; 59%	0.27	0.32	0.29	0.12
vacc., 56.9%				
prev. inf.				

Table S6. Estimated protection (and 95% CI) against infection (VE_I) and transmission (VE_T) given waning of vaccine and infection derived immunity, as of late November, 2021 in the USA, using case ratios in vaccinated and unvaccinated individuals and the timing of vaccinations and infections derived from COVID-19 deaths and vaccinations (Figures S2-S4). These estimates are derived from the rates of waning of neutralizing antibody titers (Figure 2; Table S4) and the relationship between neutralizing antibody titers and protection against infection for Delta (Figure 1; Table S3) and transmission given infection (Figure S1).

Endpoint	Estimate with waning (95% CI)
VE _{IP} (infected and unvaccinated)	0.614 (0.552-0.670)
VE _{TP} (infected and unvaccinated)	0.123 (0.086-0.178)
VEIV (vaccinated and uninfected)	0.647 (0.603-0.690)
VE _{TV} (vaccinated and uninfected)	0.155 (0.124-0.195)
VEIV (vaccinated and uninfected) NZ scenario	0.708 (0.669-0.744)
VE _{TV} (vaccinated and uninfected) NZ scenario	0.222 (0.173-0.280)
VE _{IH} (vaccinated and infected)	0.813 (0.781-0.841)
VE _{TH} (vaccinated and infected)	0.425 (0.320-0.530)
VE _{IB} (boosted with third dose)	0.872 (0.828-0.907)
VE _{TB} (boosted with third dose)	0.607 (0.423-0.765)




Figure S1. Protection against transmission given infection plotted against the ratio of neutralizing antibody titers relative to convalescent sera from infection with SARS-CoV-2 for Astrazeneca (left filled triangle) and Pfizer (right filled triangle) (21). The raw data is in Table S1 – Transmission endpoint. Open squares show the estimated protection with waning (left open square) and boosting (right open square). The fitted model is: logit(Protection) = $-0.336 \pm 0.225 \pm 0.549 \pm 0.549 \pm 0.124 \pm$




Figure S2. Number of people fully vaccinated in the USA (27).

580

581




Figure S3. COVID-19 cases, deaths, and infections inferred from deaths in the USA (25).

583

584




Figure S4. Ratio of COVID-19 cases in unvaccinated individuals relative to vaccinated individuals in the USA in 2021 based on data from CDC (29). Points show weekly estimates, and the line and ribbon shows a generalized additive model fit and 95% CI.